Computational, Technological, and Mechanistic Advances

• 974 · PDF AI-driven- structure-based drug discovery and validation of novel compounds as CTLA-4/B7 inhibitors Poonam Kalhotra, Tzayhri Gallardo-Velazquez, Guillermo Osorio-Revilla, Veera Chandra Sekhar Reddy Chittepu
• 975 Deep learning-based screening and design of novel therapeutics that reverse cancer-associated transcriptional phenotypes Jing Xing, Mingdian Tan, Dmitry Leshchiner, Mengying Sun, Shreya Paithankar, Rama Shankar, Erika Lisabeth, Bilal Aleiwi, Ruoqiao Chen, Matthew Giletto, Richard Neubig, Samuel So, Edmund Ellsworth, Mei-Sze Chua, Jiayu Zhou, Bin Chen
• 976 · PDF FGFR3-TACC3 fusion: multi-omics and machine learning characterization across tumor types Manuel Pedregal, Esther Cabañas Morafraile, Balázs Győrffy, Ester Garcia, Miriam Dorta, Bernard Gaston Doger de Spéville, Emiliano Calvo, Alberto Ocaña, Victor Moreno Garcia
• 977 · PDF VINI: A multimodal in silico platform for discovering rational drug combinations in KRAS-mutant pancreatic cancer Drasko Tomic
• 978 · PDF Deep learning frameworks for translating cancer drug response from cell-level to patient-level by modeling transcriptome Sun Kim, Bonil Koo, Dongmin Bang, Inyoung Sung, Changyun Cho, Sangseon Lee, Kyoung Jae Won
• 979 · PDF DrugVLAB for oncogenic kinase inhibitor generation Sun Kim, hyerin kim, Bokyung Park, Joonho Seong, kim youngkuk, Seokchol Hong, Changyun Cho, Heejoon Chae, Kyoung Jae Won
• 980 · PDF Multimodal chemogenomic modeling-based drug repurposing for targeted therapy of PDAC Adil Ibrahim Mohammed, Zhaowei Han, Yuanhao Huang, Zihe Meng, Jie Liu, Shuibing Chen
• 981 · PDF MTA-DTA: A multi-token attention framework for drug-target binding affinity prediction Il-san Jeong, Seung-Woo Baek, Jee-Woo Seo, Yeo-Gyeong Yoon, Jae-Yoon Kim, Seon-Young Kim, Seon-Kyu Kim
• 982 · PDF Pharmacophore profiling highlights diverging binding modes of nemtabrutinib and ibrutinib across tyrosine kinases Charly Empereur-mot, Giulio Sartori, Luca Pesce, Filippo Spriano, Chiara Tarantelli, Luciano Cascione, Alberto J. Arribas, Luca Aresu, Davide Rossi, Giovanna L.M. Damia, Massimo Broggini, Daniela Polino, Francesco Bertoni
• 983 · PDF Beyond the active site: Discovery of novel PYCR1 allosteric binding sites via structure-oriented fragment crystallographic screening Olha Tarkhanova, Kaylen R. Meeks, Juan Ji, Caitlin J. Mattingly, Jay C. Nix, Mykola Protopopov, John J. Tanner
• 984 · PDF MHC-associated peptide proteomics for immunogenicity risk assessment of immuno-oncology drug candidates Chloé Ackaert, Jana Schockaert, Aurélie Mazy, Christoph Schifflers, Martijn Vlaming, Elise Pepermans, Sofie Pattyn
• 985 · PDF Anticancer efficacy of tricarbonylperrhenato(bathophen)rhenium(I) organometallic compound in pancreatic ductal adenocarcinoma Ishita Saha, Cecilia Parpinelli, Birsen Varisli, Santosh Mandal, Santanu Bhattacharya
• 986 Silyl ethers analogs of SN-38 with unique blue-fluorescent properties exhibit potent anti-cancer activity through topoisomerase I inhibition Sanika Vaidya, Ashley Mo, Alyssa Yee-Xin Chia, Katelyn Li, Shreya Somani, Isabella Lo, Lekhya Menta, Gary Johanning, Feng Wang-Johanning, Edward Njoo
• 987 · PDF Optimization of bioinformatics parameters for DIA-based proteomics in targeted protein degradation Hui Zhou, Yi Liu, Aijuan Yu, Naizhong Zheng
• 988 Synthesis, characterization, and biological evaluation of polyisoprenylated phosphonyl ester inhibitors on triple-negative breast cancer Joshua Kofi Ablordeppey, Kweku Ofosu-Asante, Amarender Burra, Jahnissi Odoom, Desmond Kwakye, Nazarius S. Lamango
• 989 · PDF PTBP1-targeted siRNA reprograms cellular metabolism and induces apoptosis in human gastric cancer cells Hirokatsu Hayashi, Keita Matsumoto, Masashi Kuno, Masahiro Fukada, Ryuichi Asai, Yuta Sato, Itaru Yasufuku, Tajima Jesse Yu, Yoshihiro Tanaka, Manabu Futamura, Nobuhisa Matsuhashi
• 990 · PDF SR-B1 gene variants, inhibitors and the effect of glucose on IC50s in breast cancer Nandini Bhattacharya, Sree Aramgam, K. Sean Kimbro
• 991 · PDF Synergistic effects of antineoplastic drugs and gap junction enhancer in heterogenous colorectal cancer Tomas Lugo, Annelise Nguyen
• 992 A novel targeted protein degradation platform based on internalization-enhancing peptide for lysosomal degradation of cell-surface proteins Dae Young Kim, Dahye Sim, Daeho Park, Yujin Park, Hee Young Kang, Hoil Choi
• 993 · PDF From phenotypic screening to mechanistic insight: Rational discovery of chemosensitizers for glioblastoma Lukas Gorecki, Lubica Muckova, Michaela Sadibolova, Ondrej Soukup
• 994 · PDF Selective oncolysis via oncomiR-driven DNA self assembly Akimitsu Okamoto, Kunihiko Morihiro, Makoto Yamamoto
• 996 · PDF Novel sulfonamide-aromatic amine hybrids: Synthesis, cytotoxic screening, and transcriptomic insights into anticancer activity Mohamed A. Eltokhy, Eman A. Fayed, Moustafa S. Abusaif, Ahmed Ragab, Yousry A. Ammar, Sahar Radwan, Sanjay K. Srivastava
• 997 · PDF Development of polyHis-targeting chimeras (HisTACs) for targeted protein degradation Annan Sun, Dong Zhu, Hui Chen, Monica Billitti, Lingtao Jin, Dongwen Lyu, Guangrong Zheng
• 998 · PDF The NVL inhibitor benzothiazepinone targets colorectal cancer by blocking ribosome biogenesis Ye Tao, Holly Guo, Min Fang, VIshal Khivansara, Shanhai Xie, Ashley Leach, Divya Reddy, Noelle S. Williams, Arin B. Aurora, Deepak Nijhawan, Jef K. De Brabander
• 999 · PDF N/C-terminus modification: enhanced TROP2-targeting cyclic peptide for PET imaging JONGMIN AN, Nisi Zhang, Marian Awadalla, SPENCER TUMBALE, Marina Raie, Basit Jan, Katherine W. Ferrara
• 1000 Stereocontrolled synthesis and evaluation of functionalized lactams as potential anti-triple-negative breast cancer agents Leila Rahimian, Tolulope Omolekan, Ojasvi Dutta, Konstantin G. Kousoulas, Timothy K. Beng, Jean C. Chamcheu
• 1001 Targeting regulation of F-actin in cutaneous T-cell lymphoma: Synergistic inhibition of p38beta with p38gamma inhibitors Xu Hannah Zhang, Jack Hsiang, Markus Kalkum, Jun Wu, Steven T. Rosen
• 1002 · PDF Parallel drug development strategies for fibrolamellar hepatocellular carcinoma and proteasome-dependent multiple myeloma Shalini Rawat, Najmeh Rahimi, Jared Alderman, Celeste Villasenor, Rodolfo Tello-Aburto, Barbara Lyons
• 1003 Targeted co-delivery of gemcitabine and atRA via a GSH-responsive mutual prodrug enhances cytotoxicity through redox imbalance and Pin1 inhibition Nanhee Song, Ilseob Kim, Chnagjin Lim, Dongwon Lee, Sun Il Choi, Yun-Hee Kim

在完整检索应用中浏览本分会场 →